Agomab, a Ghent, Belgium-based biology treatments company, raised $100M in Series C funding.
The round was led by Fidelity Management & Research Company, with participation from new investors EQT Life Sciences, Canaan, Dawn Biopharma, and existing investors.
The company intends to use the funds to support the recently announced STENOVA Phase 2a clinical trial evaluating its lead candidate AGMB-129, a gut-restricted small molecule inhibitor of ALK5, in patients with Fibrostenosing Crohn’s Disease (FSCD).
Led by CEO Tim Knotnerus, Agomab is biology company developing novel treatments that aim to resolve fibrosis, repair tissue structure, and restore organ function. By combining new scientific insights with drug development and a long-term corporate vision, it is building a broad clinical pipeline of differentiated programs with disease modifying potential in fibrotic diseases. Its pipeline of growth factor targeting antibodies and small molecule compounds includes its lead candidate AGMB-129, a gastrointestinal tract restricted ALK5 inhibitor for which it has recently started a Phase 2a clinical trial in Fibrostenosing Crohn’s Disease and received U.S. FDA Fast Track Designation. The second TGFß targeting pipeline candidate, AGMB-447, is a Phase-1-ready lung-restricted ALK5-inhibitor for treatment of idiopathic pulmonary fibrosis. AGMB-101 is an HGF-mimetic cMET receptor agonist in IND-enabling development for the treatment of fibrotic disorders.
FinSMEs
11/10/2023